Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Fudan University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05193292CT.gov Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Intestinal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab (this asset) | Fudan University | P2 | CCC · 53 |
| Irinotecan | Pfizer | P3 | BB |
| Fluorouracilum | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Capecitabine | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Simvastatin | University of Auckland, New Zealand | P3 | BB |
| Oxaliplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | B |
| pf-08634404 | Pfizer | P3 | B |
| Catequentinib | Zhejiang University | P2 | B |
| Sgm-101 | Leiden University Medical Center | P2 | CCC |
+5 more in the Intestinal Neoplasm cohort
Other indications for Trastuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 76 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 74 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- IrinotecanPfizerBB
- FluorouracilumCancer Institute and Hospital, Chinese Academy of Medical SciencesBB
- CapecitabineCancer Institute and Hospital, Chinese Academy of Medical SciencesBB
- SimvastatinUniversity of Auckland, New ZealandBB
- OxaliplatinCancer Institute and Hospital, Chinese Academy of Medical SciencesB
Citation
Floatz Terminal. Trastuzumab in Intestinal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-intestinal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →